作者
Kevin Chiem, Desarey Morales Vasquez, Jun-Gyu Park, Roy Neal Platt, Tim Anderson, Mark R Walter, James J Kobie, Chengjin Ye, Luis Martinez-Sobrido
发表日期
2021/3/10
期刊
Journal of virology
卷号
95
期号
7
页码范围
10.1128/jvi. 02209-20
出版商
American Society for Microbiology
简介
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19), has devastated public health services and economies worldwide. Despite global efforts to contain the COVID-19 pandemic, SARS-CoV-2 is now found in over 200 countries and has caused a death toll of over 1 million human lives as of November 2020. To date, only one Food and Drug Administration (FDA)-approved therapeutic drug (remdesivir) and a monoclonal antibody (MAb), bamlanivimab, are available for the treatment of SARS-CoV-2. As with other viruses, studying SARS-CoV-2 requires the use of secondary approaches to detect the presence of the virus in infected cells. To overcome this limitation, we have generated replication-competent recombinant SARS-CoV-2 (rSARS-CoV-2) constructs expressing fluorescent (Venus or mCherry) or …
引用总数
学术搜索中的文章